Clinico-pathologic characteristics of the 254 EOC patients
| Characteristic | BTLA | ||
|---|---|---|---|
| Non-detectable (n = 105) | Detectable(n = 149) | p value | |
| Follow-up period [mean ± SD, months] | 38.2 ± 31.5 | ||
| Age [mean ± SD, years] | 53.3 ± 11.8 | ||
| FIGO stagea [early/advanced, cases] | 33/72 | 28/121 | 0.025 |
| Histologya [serous/mucinous/clear cell /endometrioid/undifferentiated, cases] | 57/0/13/24/11 | 90/1/14/24/20 | 0.471 |
| Tumor gradea,c [1&2/3, cases] | 16/86 | 19/124 | 0.712 |
| Postoperative residual tumora [< 1 cm/≥1 cm, cases] | 65/40 | 79/70 | 0.198 |
| HVEMb [median, range] | 1.05 (0.01–79.0) | 1.52 (0.04–78.2) | 0.135 |
| BTLAb [median, range] | 0 | 0.16 (0.007–24.3) | < 0.001 |
| Disease recurrencea [yes/no, cases] | 48/57 | 108/41 | < 0.001 |
| Disease-related deatha [yes/no, cases] | 18/87 | 59/90 | < 0.001 |
Abbreviations: EOC epithelial ovarian carcinoma; SD standard deviation; FIGO International Federation of Gynecology and Obstetrics; HVEM herpesvirus entry mediator; BTLA B and T lymphocyte attenuator
a By Chi-square test
b By Mann-Whitney test
c Data unavailable for nine patients